Literature DB >> 15877670

Effect of intravenous iron on haemodialysis catheter microbial colonization and blood-borne infection.

Ursula C Brewster1, Steven G Coca, Robert F Reilly, Mark A Perazella.   

Abstract

BACKGROUND: Intravenous (i.v.) iron is employed to treat absolute and relative iron deficiency in end-stage renal disease patients. However, there exists the possibility that i.v. iron increases infection risk. This pilot study examines whether i.v. iron gluconate acutely increases tunnelled haemodialysis catheter colonization, microbial growth, or blood-borne infection.
METHODS: Nineteen patients with haemodialysis catheters who met criteria to receive an i.v. iron load entered the study. Six matched patients with catheters who did not receive iron were controls. Blood aspirated from the catheter prior to initiation of haemodialysis was sent for qualitative/quantitative cultures. The study consisted of three baseline cultures, five cultures during iron (125 mg of ferric gluconate per treatment), and three cultures following iron administration. Patients were monitored for infection for 30 days following iron.
RESULTS: Fifteen iron-treated patients and six controls completed the study. Thirty-three per cent of treated patients were colonized at baseline; 66% were colonized following iron. Thirty-three per cent of controls (2/6) were colonized at baseline; no new colonization developed during follow up. Neither treated patients nor controls had significant microbial growth within catheters; one patient in the iron-treated group developed candidaemia.
CONCLUSION: Intravenous iron is not associated with acute microbial growth in catheters or clinical infection. However, a trend towards increased catheter colonization following iron administration exists.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15877670     DOI: 10.1111/j.1440-1797.2005.00384.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  7 in total

1.  Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study.

Authors:  Navdeep Tangri; Dana C Miskulin; Jing Zhou; Karen Bandeen-Roche; Wieneke M Michels; Patti L Ephraim; Aidan McDermott; Deidra C Crews; Julia J Scialla; Stephen M Sozio; Tariq Shafi; Bernard G Jaar; Klemens Meyer; L Ebony Boulware
Journal:  Nephrol Dial Transplant       Date:  2014-11-02       Impact factor: 5.992

2.  Predictors and outcome of catheter-related bacteremia in children on chronic hemodialysis.

Authors:  Ali Mirza Onder; Jayanthi Chandar; Sheila Coakley; Carolyn Abitbol; Brenda Montane; Gaston Zilleruelo
Journal:  Pediatr Nephrol       Date:  2006-08-01       Impact factor: 3.714

Review 3.  The Impact of Preoperative Intravenous Iron Therapy on Perioperative Outcomes in Cardiac Surgery: A Systematic Review.

Authors:  Kelly A Tankard; Brian Park; Ethan Y Brovman; Angela M Bader; Richard D Urman
Journal:  J Hematol       Date:  2020-10-01

Review 4.  Iron and infection in hemodialysis patients.

Authors:  Julie H Ishida; Kirsten L Johansen
Journal:  Semin Dial       Date:  2013-12-12       Impact factor: 3.455

5.  Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients.

Authors:  Hassan N Ibrahim; Robert N Foley; Rui Zhang; David T Gilbertson; Allan J Collins
Journal:  Clin J Am Soc Nephrol       Date:  2009-02-11       Impact factor: 8.237

Review 6.  Safety concerns about intravenous iron therapy in patients with chronic kidney disease.

Authors:  Lucia Del Vecchio; Selena Longhi; Francesco Locatelli
Journal:  Clin Kidney J       Date:  2016-01-06

7.  Transfusional iron overload and intravenous iron infusions modify the mouse gut microbiota similarly to dietary iron.

Authors:  Francesca La Carpia; Boguslaw S Wojczyk; Medini K Annavajhala; Abdelhadi Rebbaa; Rachel Culp-Hill; Angelo D'Alessandro; Daniel E Freedberg; Anne-Catrin Uhlemann; Eldad A Hod
Journal:  NPJ Biofilms Microbiomes       Date:  2019-09-24       Impact factor: 7.290

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.